drugset / Trial / NCT07457775
Liposomal Irinotecan in Combination With Temozolomide and Bevacizumab in Patients With Advanced STS
Phase 2
Not yet recruiting
24 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
NaSingle-groupOpen-labelTreatment
Summary
The study is expected to include 24 patients with metastatic or surgically unresectable relapsed/refractory soft tissue sarcoma confirmed by histological evidence, who have received at least one line of systemic treatment previously. The efficacy and safety of liposome irinotecan combined with temozolomide and bevacizumab in the treatment of relapsed/refractory soft tissue sarcoma will be evaluated.
Timeline
- Start
- 2026-03-31
- Primary completion
- 2028-01-31
- Completion
- 2028-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | Irinotecan | Small molecule | 56.5 mg/m2 | Intravenous |
| Subject | Temozolomide | Small molecule | 100 mg/m2 | — |